Prevalence and incidence of resistance to zidovudine and other antiretroviral drugs

American Journal of Medicine

Volumn 102, Issue 5 B, 1997, Pages 70-75

  Mayers, Douglas L ^a,b  

^a NAVAL MEDICAL RESEARCH INSTITUTE   (United States)

^b Box 207 ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; DIDANOSINE; INDINAVIR; LAMIVUDINE; PROTEIN INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE; STAVUDINE; VIRUS RNA; ZALCITABINE; ZIDOVUDINE;

CONFERENCE PAPER; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NONHUMAN; PRIORITY JOURNAL; REVERSE TRANSCRIPTION; STRAIN DIFFERENCE; VIRUS MUTATION; VIRUS STRAIN; VIRUS TRANSCRIPTION;

ANTI-HIV AGENTS; DRUG RESISTANCE, MICROBIAL; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; INCIDENCE; INDINAVIR; LAMIVUDINE; PREVALENCE; REVERSE TRANSCRIPTASE INHIBITORS; RISK FACTORS; SAQUINAVIR; STAVUDINE; TIME FACTORS; ZIDOVUDINE;

EID: 0030788884     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9343(97)00067-3     Document Type: Conference Paper

References (55)

1. Coffin JM. HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy. Science. 1995;267:483-489.
2. Larder BA. Retroviral recombination can lead to linkage of reverse transcriptase mutations that confer increased zidovudine resistance. J Virol. 1995;69:669-674.
3. Havlir DV, Richman DD. Viral dynamics of HIV: implications for drug development and therapeutic strategies. Ann Intern Med. 1996;124:984-994.
4. Condra JH, Holder DJ, Schleif WA, et al. Genetic correlates of in vivo viral resistance to the HIV-1 protease inhibitor indinavir. Fifth International Workshop on HIV Drug Resistance, Whistler, Canada, July 1996.
5. Molla A, Korneyeva M, Gao Q, et al. Ordered accumulation of mutations in HIV protease confers resistance to ritonavir. Nat Med. 1996;2:760-766.
6. Condra JH, Holder DJ, Schlief WA, et al. Bi-directional inhibition of HIV-1 drug resistance selection by combination therapy with indinavir and reverse transcriptase inhibitors. (Abstr. Th.B.932.) XIth International Conference on AIDS, Vancouver, Canada, July 1996.
7. Larder BA, Darby G, Richman DD. HIV with reduced sensitivity to zidovudine isolated during prolonged therapy. Science. 1989;243:1731-1734.
8. Rooke R, Tremblay M, Soudeyns H, et al. Isolation of drug-resistant variants of HIV-1 from patients on long-term zidovudine therapy. AIDS. 1989;3:411-415.
9. Land S, Treolar G, McPhee D, et al. Decreased in vitro susceptibility to zidovudine of HIV isolates obtained from patients with AIDS. J Infect Dis. 1990;161:326-329.
10. Richman DD, Grimes JM, Lagakos SW. Effect of stage of disease and drug dose on zidovudine susceptibility of isolates of human immunodeficiency virus. J Acquir Immun Defic Syndr. 1990;3:743-746.
11. Mayers D, Japour A, Arduino J, et al. Dideoxynucleoside resistance emerges with prolonged zidovudine monotherapy. Antimicrob Agents Cnemother. 1994;38:307-314.
12. Larder BA, Kemp SD. Multiple mutations in HIV-1 reverse transcriptase confer high-level resistance to zidovudine (AZT). Science. 1989;246:1155-1158.
13. Kellam P, Boucher CA, Larder BA. Fifth mutation in human immunodeficiency virus type 1 reverse transcriptase contributes to the development of high-level resistance to zidovudine. Proc Natl Acad Sci USA. 1992;89:1934-1938.
14. Boucher CAB, O'Sullivan E, Mulder JW, et al. Ordered appearance of zidovudine-resistant mutations during treatment of 18 human immunodeficiency virus-positive subjects. J Infect Dis. 1992;165:105-110.
15. Tudor-Williams G, St Clair MH, McKinney RE, et al. HIV-1 sensitivity to zidovudine and clinical outcome in children. Lancet. 1992;339:15-19.
16. Japour AJ, Welles S, D'Aquila RT, et al. Prevalence and clinical significance of zidovudine resistance mutations in human immunodeficiency virus isolated from patients after long-term zidovudine treatment. J Infect Dis. 1995;171:1172-1179.
17. Kozal MJ, Shafer RS, Winters MA, Katzenstein DA, Merigan TC. A mutation in HIV reverse transcriptase and decline in CD4 lymphocyte numbers in long-term zidovudine recipients. J Infect Dis. 1993;167:526-532.
18. Principi N, Marchisio P, DePasquale MP, et al. HIV-1 reverse transcriptase codon 215 mutation and clinical outcome in children treated with zidovudine. AIDS Res Hum Retroviruses. 1994;10:721-726.
19. St Clair MH, Martin JL, Tudor WG, et al. Resistance to ddl and sensitivity to AZT induced by a mutation in HIV-1 reverse transcriptase. Science. 1991;253:1557-1559.
20. Shafer RW, Kozal MJ, Winters MA, et al. Combination therapy with zidovudine and didanosine selects for drug-resistant human immunodeficiency virus type 1 strains with unique patterns of pol gene mutations. J Infect Dis. 1994;169:722-729.
21. Fitzgibbon JE, Howell RM, Haberzettl CA, et al. Human immunodeficiency virus type 1 pol gene mutations which cause decreased susceptibility to 2′,3′dideoxycytidine. Antimicrob Agents Chemother. 1992;36:153-157.
22. Gu Z, Gao Q, Fang H, et al. Identification of a mutation at codon 65 in the IKKC motif of reverse transcriptase that encodes HIV resistance to 2′,3′-dideoxycytidine and 2′,3′-dideoxy-3′-thiacytidine. Antimicrob Agents Chemotner. 1994;38:275-281.
23. Zhang D, Caliendo AM, Eron JJ, et al. Resistance to 2′,3′-dideoxycytidine conferred by a mutation in codon 65 of the HIV-1 reverse transcriptase. Antimicrob Agents Chemother. 1994;38:282-287.
24. Gao Q, Gu ZX, Parniak MA, et al. The same mutation that encodes low-level human immunodeficiency virus type-1 resistance to 2′,3′-dideoxyinosine and 2′,3′-dideoxycytidine confers high-level resistance to the (-) enantiomer of 2′,3′-dideoxy-3′-thiacytidine. Antimicrob Agents Chemotner. 1993;37:1390-1392.
25. Schinazi RF, Lloyd RJ, Nguyen M-H, et al. Characterization of human immunodeficiency viruses resistant to oxathiolane-cytosine nucleosides. Antimicrob Agents Chemotner. 1993;37:875-881.
26. Tisdale M, Kemp SD, Parry NR, Larder BA. Rapid in vitro selection of human immunodeficiency virus type 1 resistant to 3′-thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptase. Proc Natl Acad Sci USA. 1993;90:5653-5656.
27. Schuurman R, Nijhuis M, Leeuwen van R, et al. Rapid changes in human immunodeficiency viruss type 1 RNA load and appearance of drug-resistant populations in persons treated with lamivudine (3TC). J Infect Dis. 1994;171:1411-1419.
28. 3). (Abstr. 58.) Fifth International Workshop on HIV Drug Resistance, Whistler, Canada, July 1996.
29. Kuritzkes DR, Bakhtiari M, Shugarts D, et al. Resistance to lamivudine (3TC) and zidovudine (ZDV) after prolonged treatment with 3TC/ZDV. (Abstr. 57.) Fifth International Workshop on HIV Drug Resistance, Whistler, Canada, July 1996.
30. Miller V, for the FASP Resistance Study Group. Resistance to AZT and 3TC in HIV-1 isolates from patients failing antiretroviral therapy. (Abstr. 59.) Fifth International Workshop on HIV Drug Resistance, Whistler, Canada, July 1996.
31. Gu Z, Gao Q, Li X, Parniak MA, Wainberg MA. Novel mutation in the human immunodeficiency virus type 1 reverse transcriptase gene that encodes cross-resistance to 2′,3′-dideoxyinosine and 2′,3′-dideoxycytidine. J Virol. 1992;66:7128-7135.
32. Lacey SF, Larder BA. A novel mutation (V75T) in the HIV-1 reverse transcriptase confers resistance to 2′,3′-didehydro-2′,3′-dideoxythymidine (D4T) in cell culture. Antimicrob Agents Chemother. 1994;38:1428-1432.
33. Lin P-F, Samanta H, Rose RE, et al. Genotypic and phenotypic analysis of human immunodeficiency virus type 1 isolates from patients on prolonged stavudine therapy. J Infect Dis. 1994;170:1157-1164.
34. Richman DD, Havlir D, Corbeil J, et al. Nevirapine resistance mutations of human immunodeficiency virus type 1 selected during therapy. J Virol. 1994;68:1660-1666.
35. Byrnes V, Sardana W, Schleif W, et al. Comprehensive mutant enzyme and viral variant assessment of human immunodeficiency virus type-1 reverse transcriptase resistance to non-nucleoside inhibitors. Antimicrob Agents Chemother. 1993;37:1576-1579.
36. Mellors JW, Larder BA, Schinazi RF. Mutations in HIV-1 reverse transcriptase and protease associated with drug resistance. Int Antiviral News. 1995;3:8-13.
37. Richman DD. Resistance of clinical isolates of human immunodeficiency virus to antiretroviral agents. Antimicrob. Agents Chemother. 1993;37:1207-1213.
38. Larder BA. 3′-Azido-3′-deoxythymidine resistance suppressed by a mutation conferring human immunodeficiency virus type 1 resistance to non-nucleoside reverse transcriptase inhibitors. Antimicrob Agents Chemother. 1992;36:2664-2669.
39. Kozal MJ, Shah N, Shen N, et al. Extensive polymorphisms observed in HIV-1 clade B protease gene using high-density oligonucleotide arrays. Nat Med. 1996;2:753-759.
40. Jacobsen H, Markus H, Ott M, et al. In-vivo resistance to a human immunodeficiency virus type 1 proteinase inhibitor: mutations, kinetics, and frequencies. J Infect Dis. 1996;173:1379-1387.
41. Roberts NA. Drug resistance patterns of saquinavir and other HIV proteinase inhibitors. AIDS. 1995;9(suppl 2):S27-S32.
42. Shapiro JM, Winters MA, Stewart F, et al. The effect of high-dose saquinavir on viral load and CD4 T-cell counts in HIV-infected patients. Ann Intern Med. 1996;124:1039-1050.
43. Condra JH, Schleif WA, Blahy OM, et al. In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors. Nature. 1995;374:569-571.
44. Larder BA, Kemp SD, Harrigan PR. Potential mechanism of sustained antiretroviral efficacy of AZT-3TC combination therapy. Science. 1995;269:696-699.
45. Mellors JW, Bazmi HZ, Schinazi RF, et al. Novel mutations in the reverse transcriptase of human immunodeficiency virus type 1 confer resistance to foscarnet in laboratory and clinical isolates. Antimicrob Agents Chemother. 1995;39:1087-1092.
46. McLeod G, Mayers D, McCutchan F, Sanders-Buell E, Hammer S. Dideoxynucleoside resistance patterns in clinical isolates of HIV-1. (Abstr. ThA 1569.) VIII International Conference on AIDS, Amsterdam, 1992.
47. Shirasaka T, Kavlick MF, Ueno T, et al. Emergence of human immunodeficiency virus type 1 variants with resistance to multiple dideoxynucleosides in patients receiving therapy with dideoxynucleosides. Proc Natl Acad Sci USA. 1995;92:2398-2402.
48. Erice A, Mayers DL, Strike DG, et al. Brief report: primary infection caused by zidovudine-resistant human immunodeficiency virus type 1 (HIV-1). N Engl J Med. 1993;328:1163-1165.
49. Anonymous. HIV seroconversion after occupational exposure despite early prophylactic zidovudine therapy. Lancet. 1993;341:1077-1078.
50. Masquelier B, Lemoigne E, Pellegrin E, et al. Primary infection with zidovudine-resistant HIV. (Letter.) N Engl J Med. 1993;329:1123-1124.
51. Fitzgibbon JE, Gaur S, Frenkel LD, et al. Transmission from one child to another of human immunodeficiency virus type 1 with a zidovudine resistance mutation. N Engl J Med. 1993;329:1835-1841.
52. Frenkel LM, Wagner LEI, Demeter LM, et al. Effects of zidovudine use during pregnancy on resistance and vertical transmission of human immunodeficiency virus type 1. Clin Infect Dis. 1995;20:1321-1326.
53. Veenstra J, Schuurman R, Cornelissen M, et al. Transmission of zidovudine-resistant human immunodeficiency virus type 1 variants following deliberate injection of blood from a patient with AIDS: characteristics and natural history of the virus. Clin Infect Dis. 1995;21:556-560.
54. R) HIV-1 in Switzerland, Australia and the United States between 1988 and 1994. AIDS Res Hum Retrovir. 1995;11(suppl 1):S162.
55. Fang G, Burger H, Grimson R, et al. Maternal plasma HIV-1 RNA level: a determinant and threshold for mother-to-child transmission. Proc Natl Acad Sci USA. 1995;92:12100-12104.